Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

ClinicalTrials.gov ID: NCT00066586

Public ClinicalTrials.gov record NCT00066586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density. PURPOSE: Randomized clinical trial to study the effectiveness of exemestane in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density in postmenopausal women who are at increased risk for breast cancer.

Study identification

NCT ID
NCT00066586
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
NCIC Clinical Trials Group
Network
Enrollment
98 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
Up to 120 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2001
Primary completion
Nov 15, 2007
Completion
Feb 9, 2009
Last update posted
Apr 1, 2020

2001 – 2009

United States locations

U.S. sites
8
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Mayo Clinic - Jacksonville Jacksonville Florida 32224
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Brigham and Women's Hospital Boston Massachusetts 02215
Mayo Clinic Cancer Center Rochester Minnesota 55905
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Columbus Ohio 43210-1240
Memorial Hospital of Rhode Island Pawtucket Rhode Island 02860

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

Recently updated Breast Cancer trials

Other public records listing Breast Cancer. Sorted by last update posted; newest first. Not a recommendation.

All Breast Cancer trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00066586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00066586 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →